Accelerate Diagnostics

The firm placed 137 commercially contracted instruments in the quarter and 304 in the full year 2019.

The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.

Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.

The firm missed Wall Street expectations due in part to an elongated sales cycle and the timing of commercial go-lives.

Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.

The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.

The appointment of a former Roche executive as the firm's new COO is viewed as a significant event for a firm still in the early stages of driving adoption of its Pheno system.